Product Information
ACAMPROSATE CALC DR 333 MG TAB is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $0.5891 per EA under NDC 68382056928. Its NADAC has been published 479 times since Aug 2, 2017.
FDA first approved this application on May 26, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
333 mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
68382056928
Classification
Generic
Dosage Form
TABLET, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACAMPROSATE CALCIUMApproval Type
Generic (ANDA)
FDA Application
ANDA205995FDA Approved
5/26/2017
TE Code
AB
On Market Since
6/1/2017
Price Statistics
The NADAC for ACAMPROSATE CALC DR 333 MG TAB has been published 479 times since Aug 2, 2017, and over the history we have for it it has declined 32.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5891 per EA |
|---|---|
| All-time high | $0.9208 (Sep 13, 2017) |
| All-time low | $0.2971 (Nov 20, 2024) |
| 52-week high | $0.6218 |
| 52-week low | $0.5871 |
| Median price | $0.6297 |
| Average price | $0.6268 |
| Largest weekly change | +76.4% (Feb 12, 2025) |
| Weeks tracked | 479 |
| Tracking since | Aug 2, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the acamprosate calcium market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
acamprosate calcium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ACAMPROSATE CALC DR 333 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for ACAMPROSATE CALC DR 333 MG TAB, manufactured by Zydus Pharmaceuticals (USA) Inc., is $0.5891 per EA (NDC 68382056928), effective Sep 30, 2026.
How has the price of ACAMPROSATE CALC DR 333 MG TAB changed over time?
Over the history we have for it, the NADAC for ACAMPROSATE CALC DR 333 MG TAB has declined 32.7%. It has been tracked across 479 weekly CMS publications since Aug 2, 2017.
What are the highest and lowest recorded NADAC prices for ACAMPROSATE CALC DR 333 MG TAB?
Since Aug 2, 2017, the NADAC for ACAMPROSATE CALC DR 333 MG TAB has ranged from a low of $0.2971 (Nov 20, 2024) to a high of $0.9208 (Sep 13, 2017), with a median of $0.6297 per EA.
Are there cheaper alternatives to ACAMPROSATE CALC DR 333 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of ACAMPROSATE CALC DR 333 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ACAMPROSATE CALC DR 333 MG TAB?
ACAMPROSATE CALC DR 333 MG TAB (NDC 68382056928) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.